Payment & Shipping Terms | Supply Capacity |
Payment Terms: | T/T, WU | Production Capacity: | 1000kg/year |
Min. Order: | 1 Gram | Packing: | according to the customer's requirements |
Means of Transport: | Ocean, Air, Land | Delivery Date: | 7 days |
Cediranib
CAS 288383-20-0
Cediranib is an oral antitumor drug. It is a highly effective inhibitor of VEGFR tyrosine kinase and can inhibit all known VEGFR tyrosine kinases (including VEGFR-1, VEGFR-2, VEGFR-3 and PDGFR). Sildenab can inhibit VEGF induced angiogenesis, neovascularization and xenograft cell growth. In the phase I study of NSCLC patients, it was found that the combination of sildenab and PC regimen had significant antitumor effect. Phase II / III study br24 studied 30 mg of sildenab as the first-line treatment for NSCLC patients, which proved that it had antitumor effect, but the incidence of adverse events was high, including diarrhea, dehydration, hand foot syndrome, hypertension and neutropenia. Therefore, it was decided to stop the clinical trial. Repeated evaluation of the dose and toxicity of the combination indicated that part of the adverse reactions were dose-related, and it could be tried to reduce the dose to improve the drug tolerance.
We can customize according to customer's requirement
if you have any question pls mail us or call us.
